Perrigo Expands OTC Growth Strategy With Rx-To-OTC Switch Licensing For Nasonex®
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cantor Fitzgerald Remains Bullish on Perrigo (PRGO) Despite Guidance Cut
August 9, 2018 11:22 AM EDTCantor Fitzgerald analsyt Louise Chen remains positive on Perrigo Co. (NYSE: PRGO) despite lowered FY18 guidance.
Chen notes weakness was driven by headwinds in its Rx business, which it now expects to sell, merge or separate out in 2H19.... More
